What is Stevanato Group?
Stevanato Group stands as one of the world's largest integrated providers of containment and delivery solutions tailored for the biopharmaceutical and diagnostic industries. With a foundational strength in proprietary glass-forming technology, the company ensures the highest standards of quality across its diverse offerings. Stevanato Group's comprehensive capabilities span the production of glass containers under its established Ompi brand, the manufacturing of plastic components for medical devices and diagnostics, contract manufacturing services for advanced drug delivery systems, and the development of sophisticated inspection, assembly, and packaging machinery. This integrated approach positions Stevanato Group as a critical partner for life science companies navigating complex product development and manufacturing challenges.
How much funding has Stevanato Group raised?
Stevanato Group has raised a total of $1B across 3 funding rounds:
Share Placement
$672M
Debt
$137M
Debt
$235.4M
Share Placement (2021): $672M, investors not publicly disclosed
Debt (2023): $137M led by CDP Venture Capital SGR and BNP Paribas
Debt (2025): $235.4M supported by BANCO BPM, Cdp, and BNP Paribas
Key Investors in Stevanato Group
CDP Venture Capital SGR
CDP Venture Capital SGR is a leading venture capital fund manager in Italy, focusing on strategic investments in sectors crucial for Italy's growth, with a strong emphasis on innovation and sustainability in areas like digital health.
BNP Paribas
BNP Paribas is a leading international banking group providing a wide range of financial services, including corporate and institutional banking, and is known for its significant global presence and commitment to sustainable finance.
BANCO BPM
Banco BPM SpA operates as a National Commercial Bank headquartered in Milan, Italy, offering a broad spectrum of banking and financial services to individuals and businesses.
What's next for Stevanato Group?
The recent major strategic investment signifies Stevanato Group's transition into a scaling phase, likely Series B or beyond, indicating a strong market validation and investor confidence. This capital will be instrumental in expanding manufacturing capacity, enhancing research and development for next-generation containment and delivery technologies, and potentially pursuing strategic acquisitions to broaden its service portfolio. The company's focus on serving the biopharmaceutical industry, a sector characterized by high growth and stringent regulatory demands, suggests a strategic emphasis on innovation, quality assurance, and global market penetration. Future developments will likely involve further integration of its diverse offerings and strengthening its position as a comprehensive solutions provider.
See full Stevanato Group company page
